CAMP4 Therapeutics Corporation CAMP
NASDAQ · United States · Health Technology
$4.00+0.16 (+4.17%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Company anticipates initiation of the clinical trial in 4Q 2026 WATERTOWN, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics design
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.